AC
CRL icon

Annandale Capital’s Charles River Laboratories CRL Stock Holding History

Annandale Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,900
Closed -$1.87M – 139
2023
Q4 		$1.87M Buy
+7,900
New +$1.55M 0.35% 66
2022
Q3 		– Sell
-2,000
Closed -$428K – 138
2022
Q2 		$428K Buy
+2,000
New +$489K 0.17% 90

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Annandale Capital's CRL Position: Q1 2024 in Review

Annandale Capital sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 7,900 shares — an estimated $1.87M sold.

Annandale Capital first reported a position in CRL in Q2 2022 and held it in 2 quarters. The position peaked at $1.87M in Q4 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Annandale Capital reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Annandale Capital sold 7,900 Charles River Laboratories shares in Q1 2024, an estimated $1.87M.
  • Annandale Capital first reported a position in Charles River Laboratories in Q2 2022 and held it in 2 quarters.
  • Annandale Capital's Charles River Laboratories position peaked at $1.87M in Q4 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Annandale Capital's 13F filing for Q1 2024, filed 15 May 2024.